(Q93489203)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

title

Reply: SUN BEVIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

Martin Hoyle

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

author name string

Z Liu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

G Rogers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

C Green

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

T Moxham

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

K Welch

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

K Stein

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

publication date

5 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

British Journal of Cancer

7 May 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

volume

102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

page(s)

234-235

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness

7 May 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813750

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813750

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813750

A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence

11 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2813750

11 February 2021

Identifiers

DOI

10.1038/SJ.BJC.6605447

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2813750&resulttype=core&format=json

7 May 2020

1 reference